Article
Dendritic cell-based vaccines in the setting of peripheral blood stem cell transplantation: CD34+ cell-depleted mobilized peripheral blood can serve as a source of potent dendritic cells.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Nov 1998
Choi D, Perrin M, Hoffmann S, Chang A E, Ratanatharathorn V, Uberti J, McDonagh K T, Mulé J J
Abstract excerpt
We are investigating the use of tumor-pulsed dendritic cell (DC)-based vaccines in the treatment of patients with advanced cancer. In the current study, we evaluated the feasibility of obtaining both CD34+ hematopoietic stem/ progenitor cells (HSCs) and functional DCs from the same leukapheresis...
Topics
- Antigens, CD34
- Cancer Vaccines
- Cell Separation
- Cells, Cultured
- Dendritic Cells
- Feasibility Studies
- Flow Cytometry
- Granulocyte Colony-Stimulating Factor
- Hematopoietic Stem Cell Transplantation
- Hematopoietic Stem Cells
- Humans
- Immunization
- Leukapheresis